查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1662635

miRNA定序和檢測市場至2030年的預測：按產品類型、miRNA類型、樣本類型、技術、應用、最終用戶和地區的全球分析

miRNA Sequencing and Assay Market Forecasts to 2030 - Global Analysis By Product Type (miRNA Analysis Software, miRNA Sequencing Services and Other Product Types), miRNA Type, Sample Type, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的資料，全球 miRNA 定序和檢測市場預計在2024年達到 3.975億美元，到2030年達到 8.864億美元，年複合成長率為 14.3%。

miRNA定序是一種用於分析生物樣本中微型RNA（miRNA）表現圖譜的高績效技術。 miRNA 檢測是測量 miRNA 豐度或活性的實驗技術，通常使用 qRT-PCR、微陣列和次世代定序等技術。這些工具將有助於了解 miRNA 在疾病、發育和細胞反應中的作用。

根據美國國家生物技術資訊中心（NCBI）於2021年 7月發表的一篇論文，測量 miRNA（miR-195-5p、miR-23a-3p、miR-423-5p）可以實現對 COVID-19 的早期診斷，準確率達 99.9%。

個人化醫療需求日益成長

由於 miRNA 在基因調控和疾病機制中發揮著非常重要的作用，對個人化醫療的需求不斷成長推動市場的發展。透過了解個體的基因特徵，miRNA 分析可以實現標靶治療的精準醫療。個人化醫療的轉變將推動診斷、藥物開發和針對特定患者的照護的進步，增加 miRNA 定序技術在客製化醫療解決方案中的應用。

複雜資料分析

市場上複雜的資料分析面臨著許多挑戰，例如高計算成本、需要先進的生物資訊學專業知識以及資料解釋中可能存在的錯誤。這種複雜性可能導致不一致、可重複性差以及難以提取有意義的生物學見解。這可能會導致基於 miRNA 的診斷和治療方法的採用延遲，阻礙個人化醫療和臨床應用的進展。

慢性病增加

由於 miRNA 參與調節與癌症、糖尿病和心血管疾病等疾病相關的各種通路，慢性病的日益普及推動了市場的發展。 miRNA分析有助於早期診斷、監測疾病進展和製定個人化治療計劃。對精準診斷和治療策略的日益成長的需求推動了 miRNA 定序技術在慢性病管理和研究中的發展。

定序和分析高成本

市場上定序和分析的高成本限制了其應用，特別是在較小的研究實驗室和醫療保健機構。這種經濟障礙阻礙了基於 miRNA 的診斷和治療方法的廣泛採用和應用。此外，高成本減緩了研究和創新的步伐，推遲了個人化醫療的潛在突破，並減少了改善一系列疾病患者治療結果的機會。

COVID-19 的影響

新冠疫情導致研究計劃延遲、實驗室使用受限以及資源被重新分配至緊急的疫情相關需求，擾亂了市場。這阻礙了進行的研究並阻礙了基於 miRNA 的診斷和治療方法的發展。然而，這場大流行凸顯了快速準確診斷的重要性，並加速了人們對未來全球健康危機中病毒感染檢測和個人化治療方法的miRNA 技術的興趣。

預測期內，自體免疫疾病領域預計將實現最大幅度成長

miRNA 被研究作為狼瘡和多發性硬化症等自體免疫疾病的潛在生物標記。 miRNA 分析有助於了解疾病機制、確定治療目標和開發早期診斷工具。隨著研究的進展，基於miRNA的檢測有望在自體自體免疫疾病的個人化治療中發揮重要作用，提高診斷的準確性和治療效果。

預計製藥和生物技術公司在預測期內將實現最高年複合成長率

預計製藥和生物技術公司部門將在預測期內實現最高成長率。 miRNA在基因調控中發揮重要作用，其表現圖譜可為多種疾病提供見解，包括癌症和神經系統疾病。定序技術的進步使得 miRNA 表現的高通量分析成為可能，為醫藥市場中新的治療方法和改進的患者特異性治療策略提供了潛力。

佔有率最大的地區

在預測期內，北美預計將佔據最大的市場佔有率，因為它擁有先進的醫療保健基礎設施和對個人化醫療的高度重視。該地區受益於 miRNA 技術在學術和臨床領域的廣泛應用，癌症、感染疾病和遺傳疾病的研究也不斷取得進展。政府資助以及生物技術公司和研究機構之間的合作進一步推動了市場的擴張。

年複合成長率最高的地區

預計預測期內亞太地區將呈現最高的年複合成長率。特別是，人們對基於 miRNA 的研究的投入不斷增加，以了解 miRNA 在基因調控、疾病機制和治療應用中的作用。此外，個人化和精準醫療的轉變推動對 miRNA 定序的需求，因為 miRNA 可以提供有關個別基因特徵和疾病感受性的寶貴見解。

免費客製化服務

訂閱此報告的客戶可享有以下免費自訂選項之1：

  • 公司簡介
    • 對其他市場參與企業（最多3家公司）進行全面分析
    • 主要企業的SWOT 分析（最多3家公司）
  • 地理細分
    • 根據客戶興趣對主要國家進行市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭性基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 研究範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二手研究資料資訊來源
    • 先決條件

第3章 市場走勢分析

  • 介紹
  • 促進因素
  • 限制因素
  • 機會
  • 威脅
  • 產品分析
  • 技術分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19 的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭敵對

第5章 全球miRNA 定序和檢測市場（依產品類型）

  • 介紹
  • miRNA分析軟體
    • 定序耗材
    • 庫準備套件
  • miRNA定序服務
  • 其他

第6章 全球miRNA 定序與檢測市場（依 miRNA 類型）

  • 介紹
  • 保守的miRNA
  • 非保守 miRNA
  • 腫瘤細胞
  • 發育 miRNA

第7章 全球miRNA 定序和檢測市場（依樣本類型）

  • 介紹
  • 血液/血清/血漿
  • 組織樣本
  • 尿液和唾液
  • 細胞株

第8章 全球miRNA 定序和檢測市場（依技術）

  • 介紹
  • 順序
    • 新一代定序（NGS）
    • 微陣列
    • 定量聚合酵素鏈鎖反應（qPCR）
  • 奈米孔定序
  • 桑格序列測定。
  • 單分子即時（SMRT）定序

第9章 全球miRNA 定序和檢測市場（依應用）

  • 介紹
  • 癌症
  • 多聚谷氨醯胺疾病
  • 心血管疾病
  • 思覺失調症
  • 自體免疫疾病
  • 感染疾病
  • 神經系統疾病
  • 其他

第10章

  • 介紹
  • 學術研究所
  • 製藥和生物技術公司
  • 醫院和診斷實驗室
  • 合約研究組織（CRO）
  • 其他

第11章

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第12章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第13章 公司概況

  • Illumina, Inc.
  • Thermo Fisher Scientific, Inc.
  • Qiagen NV
  • Agilent Technologies, Inc.
  • Macrogen, Inc.
  • Bio-Rad Laboratories, Inc.
  • Takara Bio, Inc.
  • Exiqon A/S
  • Zymo Research Corporation
  • New England Biolabs, Inc.
  • Roche Diagnostics
  • Promega Corporation
  • Luminex Corporation
  • Boster Biological Technology
  • Bioo Scientific
Product Code: SMRC28496

According to Stratistics MRC, the Global miRNA Sequencing and Assay Market is accounted for $397.5 million in 2024 and is expected to reach $886.4 million by 2030 growing at a CAGR of 14.3% during the forecast period. miRNA sequencing is a high-throughput technique used to analyze microRNA (miRNA) expression profiles in a biological sample. It involves isolating and sequencing small RNA molecules to identify and quantify miRNAs, providing insights into gene regulation and cellular processes. miRNA assays are experimental methods to measure the abundance or activity of miRNAs, often using technologies like qRT-PCR, microarrays, or next-generation sequencing. These tools help in understanding the role of miRNAs in diseases, development, and cellular responses.

According to an article published in the National Center for Biotechnology Information (NCBI), in July 2021, early-stage diagnosis of COVID-19 may be identified with 99.9% accuracy by measuring miRNA (miR-195-5p, miR-23a-3p, and miR-423-5p).

Market Dynamics:

Driver:

Growing demand for personalized medicine

The growing demand for personalized medicine is driving the market, as miRNAs play a crucial role in gene regulation and disease mechanisms. By providing insights into individual genetic profiles, miRNA analysis enables targeted therapies and precision treatments. This shift towards personalized medicine fosters advancements in diagnostics, drug development, and patient-specific care, increasing the adoption of miRNA sequencing technologies for tailored healthcare solutions.

Restraint:

Complex data analysis

Complex data analysis in the market poses challenges such as high computational costs, the need for advanced bioinformatics expertise, and potential errors in data interpretation. These complexities can lead to inconsistencies, reduced reproducibility, and difficulties in extracting meaningful biological insights. As a result, it can slow down the adoption of miRNA-based diagnostics and therapies, hindering progress in personalized medicine and clinical applications.

Opportunity:

Increasing prevalence of chronic diseases

The increasing prevalence of chronic diseases is fueling the market, as miRNAs are involved in the regulation of various pathways associated with diseases like cancer, diabetes, and cardiovascular conditions. miRNA analysis helps in early diagnosis, monitoring disease progression, and developing personalized treatment plans. This rising demand for precise diagnostics and therapeutic strategies is driving the growth of miRNA sequencing technologies in chronic disease management and research.

Threat:

High cost of sequencing and analysis

The high cost of sequencing and analysis in the market limits accessibility, especially for smaller research labs and healthcare settings. This financial barrier hinders widespread adoption and implementation of miRNA-based diagnostics and therapies. Additionally, the expense can slow down the pace of research and innovation, delaying potential breakthroughs in personalized medicine and reducing opportunities for improving patient outcomes across various diseases.

Covid-19 Impact:

The COVID-19 pandemic disrupted the market by delaying research projects, limiting laboratory access, and diverting resources toward immediate pandemic-related needs. This caused setbacks in ongoing studies and hindered the development of miRNA-based diagnostics and treatments. However, the pandemic also highlighted the importance of rapid, precise diagnostics, accelerating interest in miRNA technologies for viral infection detection and personalized therapeutic approaches in future global health crises.

The autoimmune disease segment is expected to be the largest during the forecast period

The autoimmune disease segment is expected to account for the largest market share during the forecast period. miRNAs are being studied as potential biomarkers for autoimmune disorders like lupus, and multiple sclerosis. miRNA profiling aids in understanding disease mechanisms, identifying therapeutic targets, and developing early diagnostic tools. As research advances, miRNA-based assays are expected to play a key role in the personalized treatment of autoimmune diseases, enhancing diagnostic accuracy and therapeutic efficacy.

The pharmaceutical and biotechnology companies segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the pharmaceutical and biotechnology companies segment is predicted to witness the highest growth rate. miRNAs play a crucial role in gene regulation, and their expression profiles can reveal insights into various diseases, including cancer and neurological disorders. Advances in sequencing technologies enable high-throughput analysis of miRNA expression, offering potential for novel therapeutic approaches and improving patient-specific treatment strategies in the pharmaceutical market.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share driven by advanced healthcare infrastructureand a strong focus on personalized medicine. The region benefits from widespread adoption of miRNA technologies in both academic and clinical settings, with ongoing advancements in cancer research, infectious diseases, and genetic disorders. Government funding, along with collaborations between biotech companies and research institutions, further supports the market's expansion.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR. There is a growing investment in miRNA-based research, particularly in understanding their role in gene regulation, disease mechanisms, and therapeutic applications. Additionally, The shift toward personalized and precision medicine is boosting the demand for miRNA sequencing, as miRNAs can offer valuable insights into individual genetic profiles and disease susceptibility.

Key players in the market

Some of the key players in miRNA Sequencing and Assay market include Illumina, Inc., Thermo Fisher Scientific, Inc., Qiagen N.V., Agilent Technologies, Inc., Macrogen, Inc., Bio-Rad Laboratories, Inc., Takara Bio, Inc., Exiqon A/S, Zymo Research Corporation, New England Biolabs, Inc., Roche Diagnostics, Promega Corporation, Luminex Corporation, Boster Biological Technology, and Bioo Scientific.

Key Developments:

In November 2024, QIAGEN announced the launch of two new tools for designing and ordering custom solutions that can be used to support microbial analysis of bacterial, fungal and viral targets. hese new tools enable researchers to customize their assays and panels for use on the QIAcuity digital PCR system as well as on any third-party next-generation sequencing (NGS) system.

In September 2024, QIAGEN announced an important milestone with the launch of 100 new assays for its digital PCR (dPCR) platform QIAcuity for use in the study of cancer, inherited genetic disorders, infectious disease surveillance, and food and environmental monitoring.

Product Types Covered:

  • miRNA Analysis Software
  • miRNA Sequencing Services
  • Other Product Types

miRNA Types Covered:

  • Conserved miRNAs
  • Non-Conserved miRNAs
  • OncomiRs
  • Developmental miRNAs

Sample Types Covered:

  • Blood/Serum/Plasma
  • Tissue Samples
  • Urine and Saliva
  • Cell Lines

Technologies Covered:

  • Sequencing
  • Nanopore Sequencing
  • Sanger Sequencing.
  • Single Molecule Real-time (SMRT) Sequencing

Applications Covered:

  • Cancer
  • Polyglutamine Diseases
  • Cardiovascular Diseases
  • Schizophrenia
  • Autoimmune Disease
  • Infectious Diseases
  • Neurological Disorders
  • Other Applications

End Users Covered:

  • Academic and Research Institutes
  • Pharmaceutical and Biotechnology Companies
  • Hospitals and Diagnostic Laboratories
  • Contract Research Organizations (CROs)
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 Application Analysis
  • 3.9 End User Analysis
  • 3.10 Emerging Markets
  • 3.11 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global miRNA Sequencing and Assay Market, By Product Type

  • 5.1 Introduction
  • 5.2 miRNA Analysis Software
    • 5.2.1 Sequencing Consumables
    • 5.2.2 Library Preparation Kits
  • 5.3 miRNA Sequencing Services
  • 5.4 Other Product Types

6 Global miRNA Sequencing and Assay Market, By miRNA Type

  • 6.1 Introduction
  • 6.2 Conserved miRNAs
  • 6.3 Non-Conserved miRNAs
  • 6.4 OncomiRs
  • 6.5 Developmental miRNAs

7 Global miRNA Sequencing and Assay Market, By Sample Type

  • 7.1 Introduction
  • 7.2 Blood/Serum/Plasma
  • 7.3 Tissue Samples
  • 7.4 Urine and Saliva
  • 7.5 Cell Lines

8 Global miRNA Sequencing and Assay Market, By Technology

  • 8.1 Introduction
  • 8.2 Sequencing
    • 8.2.1 Next-Generation Sequencing (NGS)
    • 8.2.2 Microarray
    • 8.2.3 Quantitative Polymerase Chain Reaction (qPCR)
  • 8.3 Nanopore Sequencing
  • 8.4 Sanger Sequencing.
  • 8.5 Single Molecule Real-time (SMRT) Sequencing

9 Global miRNA Sequencing and Assay Market, By Application

  • 9.1 Introduction
  • 9.2 Cancer
  • 9.3 Polyglutamine Diseases
  • 9.4 Cardiovascular Diseases
  • 9.5 Schizophrenia
  • 9.6 Autoimmune Disease
  • 9.7 Infectious Diseases
  • 9.8 Neurological Disorders
  • 9.9 Other Applications

10 Global miRNA Sequencing and Assay Market, By End User

  • 10.1 Introduction
  • 10.2 Academic and Research Institutes
  • 10.3 Pharmaceutical and Biotechnology Companies
  • 10.4 Hospitals and Diagnostic Laboratories
  • 10.5 Contract Research Organizations (CROs)
  • 10.6 Other End Users

11 Global miRNA Sequencing and Assay Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Illumina, Inc.
  • 13.2 Thermo Fisher Scientific, Inc.
  • 13.3 Qiagen N.V.
  • 13.4 Agilent Technologies, Inc.
  • 13.5 Macrogen, Inc.
  • 13.6 Bio-Rad Laboratories, Inc.
  • 13.7 Takara Bio, Inc.
  • 13.8 Exiqon A/S
  • 13.9 Zymo Research Corporation
  • 13.10 New England Biolabs, Inc.
  • 13.11 Roche Diagnostics
  • 13.12 Promega Corporation
  • 13.13 Luminex Corporation
  • 13.14 Boster Biological Technology
  • 13.15 Bioo Scientific

List of Tables

  • Table 1 Global miRNA Sequencing and Assay Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global miRNA Sequencing and Assay Market Outlook, By Product Type (2022-2030) ($MN)
  • Table 3 Global miRNA Sequencing and Assay Market Outlook, By miRNA Analysis Software (2022-2030) ($MN)
  • Table 4 Global miRNA Sequencing and Assay Market Outlook, By Sequencing Consumables (2022-2030) ($MN)
  • Table 5 Global miRNA Sequencing and Assay Market Outlook, By Library Preparation Kits (2022-2030) ($MN)
  • Table 6 Global miRNA Sequencing and Assay Market Outlook, By miRNA Sequencing Services (2022-2030) ($MN)
  • Table 7 Global miRNA Sequencing and Assay Market Outlook, By Other Product Types (2022-2030) ($MN)
  • Table 8 Global miRNA Sequencing and Assay Market Outlook, By miRNA Type (2022-2030) ($MN)
  • Table 9 Global miRNA Sequencing and Assay Market Outlook, By Conserved miRNAs (2022-2030) ($MN)
  • Table 10 Global miRNA Sequencing and Assay Market Outlook, By Non-Conserved miRNAs (2022-2030) ($MN)
  • Table 11 Global miRNA Sequencing and Assay Market Outlook, By OncomiRs (2022-2030) ($MN)
  • Table 12 Global miRNA Sequencing and Assay Market Outlook, By Developmental miRNAs (2022-2030) ($MN)
  • Table 13 Global miRNA Sequencing and Assay Market Outlook, By Sample Type (2022-2030) ($MN)
  • Table 14 Global miRNA Sequencing and Assay Market Outlook, By Blood/Serum/Plasma (2022-2030) ($MN)
  • Table 15 Global miRNA Sequencing and Assay Market Outlook, By Tissue Samples (2022-2030) ($MN)
  • Table 16 Global miRNA Sequencing and Assay Market Outlook, By Urine and Saliva (2022-2030) ($MN)
  • Table 17 Global miRNA Sequencing and Assay Market Outlook, By Cell Lines (2022-2030) ($MN)
  • Table 18 Global miRNA Sequencing and Assay Market Outlook, By Technology (2022-2030) ($MN)
  • Table 19 Global miRNA Sequencing and Assay Market Outlook, By Sequencing (2022-2030) ($MN)
  • Table 20 Global miRNA Sequencing and Assay Market Outlook, By Next-Generation Sequencing (NGS) (2022-2030) ($MN)
  • Table 21 Global miRNA Sequencing and Assay Market Outlook, By Microarray (2022-2030) ($MN)
  • Table 22 Global miRNA Sequencing and Assay Market Outlook, By Quantitative Polymerase Chain Reaction (qPCR) (2022-2030) ($MN)
  • Table 23 Global miRNA Sequencing and Assay Market Outlook, By Nanopore Sequencing (2022-2030) ($MN)
  • Table 24 Global miRNA Sequencing and Assay Market Outlook, By Sanger Sequencing. (2022-2030) ($MN)
  • Table 25 Global miRNA Sequencing and Assay Market Outlook, By Single Molecule Real-time (SMRT) Sequencing (2022-2030) ($MN)
  • Table 26 Global miRNA Sequencing and Assay Market Outlook, By Application (2022-2030) ($MN)
  • Table 27 Global miRNA Sequencing and Assay Market Outlook, By Cancer (2022-2030) ($MN)
  • Table 28 Global miRNA Sequencing and Assay Market Outlook, By Polyglutamine Diseases (2022-2030) ($MN)
  • Table 29 Global miRNA Sequencing and Assay Market Outlook, By Cardiovascular Diseases (2022-2030) ($MN)
  • Table 30 Global miRNA Sequencing and Assay Market Outlook, By Schizophrenia (2022-2030) ($MN)
  • Table 31 Global miRNA Sequencing and Assay Market Outlook, By Autoimmune Disease (2022-2030) ($MN)
  • Table 32 Global miRNA Sequencing and Assay Market Outlook, By Infectious Diseases (2022-2030) ($MN)
  • Table 33 Global miRNA Sequencing and Assay Market Outlook, By Neurological Disorders (2022-2030) ($MN)
  • Table 34 Global miRNA Sequencing and Assay Market Outlook, By Other Applications (2022-2030) ($MN)
  • Table 35 Global miRNA Sequencing and Assay Market Outlook, By End User (2022-2030) ($MN)
  • Table 36 Global miRNA Sequencing and Assay Market Outlook, By Academic and Research Institutes (2022-2030) ($MN)
  • Table 37 Global miRNA Sequencing and Assay Market Outlook, By Pharmaceutical and Biotechnology Companies (2022-2030) ($MN)
  • Table 38 Global miRNA Sequencing and Assay Market Outlook, By Hospitals and Diagnostic Laboratories (2022-2030) ($MN)
  • Table 39 Global miRNA Sequencing and Assay Market Outlook, By Contract Research Organizations (CROs) (2022-2030) ($MN)
  • Table 40 Global miRNA Sequencing and Assay Market Outlook, By Other End Users (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.